JP2010540525A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010540525A5 JP2010540525A5 JP2010526944A JP2010526944A JP2010540525A5 JP 2010540525 A5 JP2010540525 A5 JP 2010540525A5 JP 2010526944 A JP2010526944 A JP 2010526944A JP 2010526944 A JP2010526944 A JP 2010526944A JP 2010540525 A5 JP2010540525 A5 JP 2010540525A5
- Authority
- JP
- Japan
- Prior art keywords
- halo
- optionally substituted
- alkyl
- hydrogen
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001475 halogen functional group Chemical group 0.000 claims 76
- 229910052739 hydrogen Inorganic materials 0.000 claims 39
- 239000001257 hydrogen Substances 0.000 claims 39
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 36
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 34
- 125000000217 alkyl group Chemical group 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000003118 aryl group Chemical group 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 14
- 239000011780 sodium chloride Substances 0.000 claims 14
- 239000012453 solvate Substances 0.000 claims 14
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 5
- 125000005418 aryl aryl group Chemical group 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010052739 Immunodeficiency disorder Diseases 0.000 claims 1
- 206010022114 Injury Diseases 0.000 claims 1
- 208000009856 Lung Disease Diseases 0.000 claims 1
- 208000002780 Macular Degeneration Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000006641 Skin Disease Diseases 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000010425 asbestos Substances 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 244000045947 parasites Species 0.000 claims 1
- 229910052895 riebeckite Inorganic materials 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 0 *C(CCC(N1)O)(C1O)N(C(*)=NC1=C2CCC=C1*)C2=O Chemical compound *C(CCC(N1)O)(C1O)N(C(*)=NC1=C2CCC=C1*)C2=O 0.000 description 1
- FZYDOMZNKUYWTR-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=NC(C(CC(Cl)=C2)Cl)=C2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=NC(C(CC(Cl)=C2)Cl)=C2C1=O FZYDOMZNKUYWTR-UHFFFAOYSA-N 0.000 description 1
- BJJPMDJZCMOFPZ-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc(cc(c(OC)c2)OC)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc(cc(c(OC)c2)OC)c2C1=O BJJPMDJZCMOFPZ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99567607P | 2007-09-26 | 2007-09-26 | |
| US60/995,676 | 2007-09-26 | ||
| PCT/US2008/011124 WO2009042177A1 (en) | 2007-09-26 | 2008-09-25 | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010540525A JP2010540525A (ja) | 2010-12-24 |
| JP2010540525A5 true JP2010540525A5 (US07794700-20100914-C00152.png) | 2011-11-17 |
| JP5637852B2 JP5637852B2 (ja) | 2014-12-10 |
Family
ID=40225265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010526944A Active JP5637852B2 (ja) | 2007-09-26 | 2008-09-25 | ６、７又は８置換キナゾリノン誘導体並びにそれらを含有する組成物及びそれらを使用する方法 |
Country Status (22)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5388854B2 (ja) | 2006-09-26 | 2014-01-15 | セルジーン コーポレイション | ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法 |
| US8354417B2 (en) * | 2007-09-26 | 2013-01-15 | Celgene Corporation | Solid forms comprising 3-(2,5-dimethyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same |
| ME02151B (me) * | 2009-08-31 | 2015-10-20 | Merck Sharp & Dohme | Piranil aril metil benzohinazolinon kao pozitivni alosterni modulatori receptora m1 |
| WO2011049731A1 (en) | 2009-10-21 | 2011-04-28 | Merck Sharp & Dohme Corp. | Quinolinone-pyrazolone m1 receptor positive allosteric modulators |
| DK2683708T3 (da) | 2011-03-11 | 2018-01-29 | Celgene Corp | Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf |
| AR085651A1 (es) * | 2011-03-11 | 2013-10-16 | Celgene Corp | Metodos para tratar cancer usando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona |
| AU2012236655B2 (en) | 2011-03-28 | 2016-09-22 | Deuterx, Llc, | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| CA2935495C (en) | 2013-01-14 | 2021-04-20 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| EP2968334A4 (en) * | 2013-03-14 | 2016-08-03 | Deuterx Llc | 3- (SUBSTITIERTES-4-OXO-quinazolin-3 (4H) -yl) -3-deutero-PIPERIDINE-2,6-DIONE DERIVATIVES |
| CA2909625C (en) | 2013-04-17 | 2021-06-01 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
| TW201534305A (zh) * | 2013-05-03 | 2015-09-16 | Celgene Corp | 使用組合療法治療癌症之方法 |
| HUE061382T2 (hu) | 2014-08-22 | 2023-06-28 | Celgene Corp | Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva |
| KR20180023968A (ko) | 2015-07-02 | 2018-03-07 | 셀진 코포레이션 | 혈액암 및 충실성 종양의 치료를 위한 병용 요법 |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| EP3404024B1 (en) | 2016-01-14 | 2020-11-18 | Kangpu Biopharmaceuticals, Ltd. | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| WO2018208123A1 (ko) * | 2017-05-12 | 2018-11-15 | 한국화학연구원 | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 |
| KR102014478B1 (ko) | 2017-05-12 | 2019-08-26 | 한국화학연구원 | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 |
| WO2018237026A1 (en) | 2017-06-20 | 2018-12-27 | C4 Therapeutics, Inc. | N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS |
| CN111278816B (zh) | 2017-09-04 | 2024-03-15 | C4医药公司 | 二氢喹啉酮 |
| EP3679026A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Glutarimide |
| CN111315735B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 二氢苯并咪唑酮 |
| CA3079959A1 (en) * | 2017-10-27 | 2018-10-26 | Transfusion Health, Llc | Compositions and methods of making expanded hematopoietic stem cells using derivatives of fluorene |
| WO2019099868A2 (en) | 2017-11-16 | 2019-05-23 | C4 Therapeutics, Inc. | Degraders and degrons for targeted protein degradation |
| WO2019191112A1 (en) | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| CN112312904A (zh) | 2018-04-16 | 2021-02-02 | C4医药公司 | 螺环化合物 |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| CN113677664A (zh) | 2019-04-12 | 2021-11-19 | C4医药公司 | Ikaros和aiolos的三环降解物 |
| US11807620B2 (en) | 2020-02-21 | 2023-11-07 | Plexium, Inc. | Quinazolinone compounds and related compounds |
| WO2022033548A1 (zh) * | 2020-08-14 | 2022-02-17 | 上海科技大学 | 免疫调节化合物及其抗肿瘤应用 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| US5770589A (en) | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| IT1274549B (it) | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
| US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
| EA002905B1 (ru) * | 1996-05-15 | 2002-10-31 | Пфайзер Инк. | 2,3-двузамещенные-4(3н)-хиназолиноны и содержащая их фармацевтическая композиция |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| DE69740140D1 (de) | 1996-07-24 | 2011-04-14 | Celgene Corp | Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen |
| HUP0102113A3 (en) * | 1998-03-16 | 2003-03-28 | Celgene Corp Warren | 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines |
| US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
| US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
| US6001368A (en) | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
| US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| CN1511420A (zh) | 2001-11-09 | 2004-07-07 | 松下电器产业株式会社 | 运动图像编码方法和装置 |
| US7381730B2 (en) | 2002-03-15 | 2008-06-03 | Bristol-Myers Squibb Company | 3-arylquinazoline derivatives as selective estrogen receptor beta modulators |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US7211580B2 (en) * | 2002-07-23 | 2007-05-01 | Cytokinetics, Incorporated | Compounds, compositions, and methods |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| GB0324790D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
| US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| MXPA06006061A (es) | 2003-12-02 | 2006-08-11 | Celgene Corp | Metodos y composiciones para el tratamiento y manejo de la hemoglinopatia y la anemia. |
| US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| EP1737453A4 (en) | 2004-03-22 | 2008-11-26 | Celgene Corp | METHOD FOR THE USE OF IMMUNOMODULATORY COMPOUNDS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF SKIN DISEASES OR DISORDERS |
| CA2563038C (en) * | 2004-04-02 | 2013-10-29 | Gaik Beng Kok | Neurologically-active compounds |
| AU2005237490A1 (en) | 2004-04-23 | 2005-11-10 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension |
| MXPA06014696A (es) * | 2004-06-15 | 2007-02-12 | Astrazeneca Ab | Quinazolonas sustituidas como agentes anticancerosos. |
| WO2006053160A2 (en) | 2004-11-12 | 2006-05-18 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases |
| CN101102771A (zh) | 2004-11-23 | 2008-01-09 | 细胞基因公司 | 用免疫调节化合物治疗和控制中枢神经系统损伤的方法和组合物 |
| JP5775245B2 (ja) | 2004-12-01 | 2015-09-09 | セルジーン コーポレイション | 免疫不全障害の治療のために免疫調節化合物を用いる方法及び組成物 |
| CA2620085C (en) | 2005-08-31 | 2016-07-12 | Celgene Corporation | Isoindole-imide compounds and compositions comprising and methods of using the same |
| DE602006020300D1 (de) | 2005-09-01 | 2011-04-07 | Celgene Corp | Immunologische verwendungen von immunmodulatorischen verbindungen für einen impfstoff und therapie gegen infektionskrankheiten |
| JP5388854B2 (ja) * | 2006-09-26 | 2014-01-15 | セルジーン コーポレイション | ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法 |
-
2008
- 2008-09-25 BR BRPI0817525-0A2A patent/BRPI0817525A2/pt not_active Application Discontinuation
- 2008-09-25 MY MYPI2010001343A patent/MY157495A/en unknown
- 2008-09-25 MX MX2010003355A patent/MX347987B/es active IP Right Grant
- 2008-09-25 US US12/238,354 patent/US8492395B2/en active Active
- 2008-09-25 NZ NZ584425A patent/NZ584425A/en not_active IP Right Cessation
- 2008-09-25 SG SG10201503486XA patent/SG10201503486XA/en unknown
- 2008-09-25 EP EP08834539.2A patent/EP2200999B1/en active Active
- 2008-09-25 WO PCT/US2008/011124 patent/WO2009042177A1/en active Application Filing
- 2008-09-25 CA CA2704710A patent/CA2704710C/en not_active Expired - Fee Related
- 2008-09-25 AU AU2008305581A patent/AU2008305581C1/en not_active Ceased
- 2008-09-25 CN CN201410362879.4A patent/CN104211684A/zh active Pending
- 2008-09-25 SG SG2011080553A patent/SG176442A1/en unknown
- 2008-09-25 CN CN200880117819.9A patent/CN101952272B/zh not_active Expired - Fee Related
- 2008-09-25 KR KR1020107008968A patent/KR101593242B1/ko not_active IP Right Cessation
- 2008-09-25 ES ES08834539.2T patent/ES2523925T3/es active Active
- 2008-09-25 JP JP2010526944A patent/JP5637852B2/ja active Active
- 2008-09-25 RU RU2010116273/04A patent/RU2476432C2/ru not_active IP Right Cessation
- 2008-09-25 UA UAA201004853A patent/UA102078C2/ru unknown
-
2010
- 2010-03-25 IL IL204763A patent/IL204763A/en active IP Right Grant
- 2010-03-25 NI NI201000041A patent/NI201000041A/es unknown
- 2010-03-31 ZA ZA2010/02303A patent/ZA201002303B/en unknown
- 2010-04-07 CR CR11355A patent/CR11355A/es unknown
- 2010-04-20 CO CO10046034A patent/CO6270228A2/es not_active Application Discontinuation
- 2010-07-05 HK HK10106484.8A patent/HK1139934A1/xx not_active IP Right Cessation
-
2013
- 2013-06-11 IL IL226870A patent/IL226870A/en active IP Right Grant
- 2013-06-26 US US13/928,147 patent/US9096573B2/en active Active
-
2015
- 2015-06-24 US US14/749,448 patent/US9586929B2/en active Active
-
2017
- 2017-01-25 US US15/415,332 patent/US9834538B2/en active Active
- 2017-11-07 US US15/806,254 patent/US20180118713A1/en not_active Abandoned
